uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 2.90 0.00 0.00 0.00 0.00
Piotroski F-Score
3 2 3 4 3 5 1 3 6 5
P/S ratio
5.86 41.50 91.03 393.68 42.83 1.82 9.59 20.85 31.68 85.48
Altman Z-Score
(2.60) (0.78) 3.73 11.71 6.47 4.69 1.78 (1.46) (2.22) (0.80)
Altman Z″-Score (non-manufacturers)
(4.62) (4.41) (1.35) 1.25 (2.87) 8.47 1.86 (0.87) (4.73) (1.71)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 3.55 0.00 0.00 0.00 0.00
Beneish M-Score
(1.06) (3.93) (3.80) 2.46 2.04 9.33 3.29 (3.21) (2.41) (2.95)
P/Operating CF
(9.38) (30.14) (57.05) (110.22) (43.22) (20.25) (18.67) (6.67) (16.26) (17.74)
P/B ratio
2.31 6.09 5.72 8.87 6.59 1.60 2.14 1.59 0.00 6.92
Price to Tangible BV
2.68 6.86 5.91 9.04 6.69 1.89 2.61 2.73 0.00 13.66
EV/Sales
1.38 30.93 74.08 347.87 37.47 0.97 7.31 (11.21) 20.32 50.40
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 1.59 0.00 0.66 0.00 0.00
EV/Operating CF
(0.48) (6.31) (10.99) (25.67) (10.42) 1.76 (5.37) 1.22 (3.02) (4.56)
EV/FCF
(0.39) (5.80) (10.41) (24.05) (9.74) 1.89 (4.72) 1.14 (2.93) (4.49)
Quick Ratio
6.24 8.37 11.77 11.97 9.20 16.73 6.00 8.44 9.32 9.99
Current Ratio
6.34 8.47 11.85 12.15 9.47 17.09 6.28 8.85 9.74 10.43
Net Debt/EBITDA
1.70 2.17 2.52 2.99 1.82 (1.43) 1.86 1.90 1.84 3.36
Debt/Assets
10.64% 9.92% 15.96% 8.04% 10.46% 12.48% 14.58% 12.23% 9.22% 6.02%
Debt/Equity
0.32 0.23 0.24 0.11 0.15 0.17 0.22 0.49 (7.60) 0.25
Asset Turnover
0.11 0.07 0.05 0.02 0.10 0.91 0.14 0.02 0.04 0.02
Operating CF/Net income
0.98 0.81 0.91 0.79 1.08 0.87 1.14 0.47 0.76 0.89
Capex/Depreciation
(2.82) (0.74) (0.34) (1.00) (0.89) (2.39) (2.07) (0.60) (0.27) (0.03)
Interest Coverage
(33.12) (31.96) (40.85) (31.80) (32.79) 41.56 (12.23) (6.81) (2.89) (2.99)
ROE
(76.61%) (103.61%) (61.94%) (49.42%) (44.10%) 78.50% (23.66%) (90.24%) (238.46%) (207.10%)
ROA
(32.40%) (39.64%) (34.46%) (34.38%) (31.69%) 57.34% (16.75%) (40.15%) (34.51%) (28.81%)
ROIC
0.00% 0.00% 0.00% 0.00% (226.63%) 138.19% (39.60%) 0.00% 0.00% 0.00%
Return on Tangible Assets
(46.76%) (44.57%) (33.89%) (32.57%) (47.37%) 51.91% (28.09%) (49.38%) (64.63%) (32.79%)
Average Days of Receivables
133.50 44.17 7.54 47.47 64.39 40.94 350.92 96.60 79.15 132.94
Research and Development Expense of Revenue
288.91% 550.64% 662.97% 1,301.15% 326.28% 27.39% 185.56% 1,356.21% 530.19% 873.85%
Selling, General and Administrative Expense of Revenue
103.59% 187.95% 224.26% 460.71% 113.50% 10.74% 51.71% 470.81% 194.17% 406.61%
Intangible Assets out of Total Assets
0.05 0.05 0.02 0.01 0.01 0.11 0.12 0.10 0.17 0.12
Share Based Compensation of Revenue
24.76% 78.43% 94.90% 240.80% 58.19% 4.89% 32.12% 221.50% 82.08% 109.82%
Graham Net Nets
0.12 0.08 0.14 0.09 0.10 0.44 0.24 0.08 (0.20) 0.02
Graham Number
0.00 0.00 0.00 0.00 0.00 45.65 0.00 0.00 3.92 0.00
Earnings Yield
(52.47%) (14.58%) (8.12%) (4.35%) (7.78%) 34.47% (12.41%) (93.51%) (27.92%) (14.42%)
Free Cash Flow Yield
(61.09%) (12.84%) (7.82%) (3.67%) (8.98%) 28.13% (16.16%) (47.01%) (21.92%) (13.13%)
Revenue per Share
1.00 0.49 0.32 0.18 0.84 11.39 2.28 0.33 0.56 0.28
Operating CF per Share
(2.88) (2.38) (2.13) (2.47) (3.03) 6.26 (3.10) (3.06) (3.76) (3.09)
Capex per Share
(0.69) (0.21) (0.12) (0.17) (0.21) (0.38) (0.38) (0.15) (0.07) (0.01)
Free Cash Flow per Share
(3.57) (2.59) (2.25) (2.63) (3.25) 5.88 (3.48) (3.21) (3.83) (3.10)
Cash per Share
5.29 5.91 6.59 9.44 5.51 12.10 7.55 12.96 7.55 10.83
Shareholders Equity per Share
2.54 3.31 5.04 8.08 5.49 12.96 10.19 4.36 (0.14) 3.46
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
2.54 3.31 5.04 8.08 5.49 12.96 10.19 4.36 (0.14) 3.46
Free Cash Flow
(89.36) (69.85) (80.28) (105.33) (144.31) 270.52 (162.75) (153.08) (186.10) (178.40)
Working Capital
121.23 143.55 216.61 352.58 231.58 591.48 400.86 578.18 350.24 593.07
Capital Expenditures
(17.17) (5.58) (4.24) (6.65) (9.48) (17.44) (17.69) (7.15) (3.37) (0.44)
Net Current Asset Value
17.31 42.50 142.28 258.63 162.42 414.84 247.82 27.83 (173.00) 29.98
EV/EBIT
0.00 0.00 0.00 0.00 0.00 1.63 0.00 0.63 0.00 0.00
Capex to Sales
0.68 0.43 0.38 0.91 0.25 0.03 0.17 0.45 0.12 0.03
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 3.07 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.17 0.22 0.43 0.23 0.33 0.17 0.17 0.26 0.62 1.07
Cash ROIC
(41.30%) (25.92%) (17.52%) (14.29%) (27.52%) 21.59% (17.47%) (16.51%) (45.16%) (20.48%)
Accounts Receivable Turnover
3.77 2.43 12.41 12.34 9.92 16.03 1.32 0.30 5.38 2.74
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 10.29 0.50 1.55 2.65 0.27
Inventory Turnover
0.00 — — — — 0.00 0.90 1.44 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 28.30 1,199.27 176.39 143.93 1,119.25
Days of Inventory on Hand
0.00 — — — — 0.00 755.99 322.04 0.00 0.00
Average Receivables
6.65 5.38 0.91 0.59 3.78 32.69 80.57 53.28 5.04 5.87
Average Payables
4.79 4.22 3.35 4.74 4.73 3.14 6.74 8.79 6.91 6.20
Average Inventory
0.48 — — — — — 3.70 9.47 — —
Average Assets
226.46 199.95 241.78 361.27 394.51 574.79 757.07 768.33 694.11 690.72
Average Common Equity
95.78 76.50 134.48 251.33 283.48 419.84 535.89 341.84 100.46 96.07

Fold the line items

Columns are period end dates